Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first‐line oral therapy for type 2 diabetes: A claims‐based observational cohort study. Issue 12 (31st August 2021)

• Record Type: Journal Article
• Authors: Olufade, Temitope; Jiang, Like; Israni, Rubeen; Huang, Joanna; Gosmanov, Aidar R.
• Is Part Of: Diabetes, obesity & metabolism. Volume 23:Issue 12(2021)
• Page Start: 2741
• Page End: 2751
• Publication Date: 2021-08-31
• Subjects: cardiovascular disease -- chronic kidney disease -- diabetic nephropathy -- heart failure -- observational study -- resource utilization -- sodium‐glucose co‐transporter‐2 inhibitor -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14530
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aim: To examine incident cardiovascular disease (CVD) and chronic kidney disease (CKD) diagnosis and associated healthcare resource utilization (HCRU) in a real‐world population of patients with type 2 diabetes (T2D) initiating first‐line oral antidiabetes drug (OAD) therapy. Materials and Methods: Adults with T2D without CVD/CKD initiating first‐line OAD therapy from 2008 to 2018 IBM MarketScan claims data were included. Incident CVD/CKD diagnoses following OAD initiation and first diagnosis type were assessed. Risk of incident diagnosis of heart failure (HF) among patients with CKD and of CKD among patients with HF was evaluated. HCRU and costs were compared for the 12 months before and after the first CVD/CKD diagnosis. Results: Of 12 286 016 patients, 1 286 287 met all the inclusion criteria. During follow‐up (mean 752 days), 205 865 (16.0%) patients had CVD/CKD diagnoses; the most common first diagnosis was the composite cardiorenal outcome of HF and/or CKD (64.6%). Most first diagnoses were within 2 years of OAD initiation. For HF and CKD, diagnosis of one was associated with increased risk of subsequent diagnosis of the other (both P < .001). Average annualized visits per patient increased by 31% after the first CVD/CKD diagnosis and annualized payer and patient costs increased by 75% and 26%, respectively, compared with the 12 months prediagnosis. Costs increased for all diagnosis types. Conclusions: Most first CVD/CKD diagnoses occurred within 2 years after OAD initiation and were associated with increased HCRU and costs. Reducing CVD/CKD risk with T2D treatments that improve both cardiovascular and renal outcomes may attenuate the burden of illness.